Thalidomide and Phocomelia: The Teratogen That Changed Drug Regulation

Thalidomide is the prototypical human teratogen, causing severe congenital malformations—most notably phocomelia (limb reduction defects)—when taken during early pregnancy. Its tragedy catalyzed modern pharmacovigilance and teratogenicity testing requirements.

Historical Context

• Marketed 1957–1961 as sedative/antiemetic for morning sickness (West Germany, UK, Canada, others)
• Never approved in US (FDA reviewer Frances Kelsey blocked it over insufficient data)
• ~10,000–20,000 affected infants globally; ~40% mortality
• Withdrawn 1961 after McBride (Australia) and Lenz (Germany) linked it to birth defects

Teratogenic Mechanism

• Critical window: Days 20–36 post-fertilization (limb bud development)
• Mechanisms: Binds cereblon (CRBN) → alters CRL4 E3 ubiquitin ligase → degrades transcription factors (SALL4, others) → disrupts limb outgrowth, angiogenesis, neural development
• Anti-angiogenic: Inhibits VEGF/FGF signaling in developing limbs
• Oxidative stress: Generates ROS in embryonic tissues

Spectrum of Defects

• Phocomelia: Hands/feet attached to trunk (long bones absent/hypoplastic) — hallmark
• Amelia: Complete limb absence
• Other: Cardiac (VSD, ASD), GI (atresias), renal, ocular (coloboma), facial (microtia, cleft), auditory nerve
• Autonomic neuropathy: Absent tears, temperature dysregulation

Regulatory Legacy

• Kefauver-Harris Amendment (1962, US): Required proof of efficacy + safety; mandated informed consent; FDA authority over clinical trials
• Pregnancy categories: Established (now replaced by PLLR narrative labeling)
• Teratogenicity testing: Mandatory in multiple species (rodent + non-rodent)
• Pharmacovigilance systems: Spontaneous reporting, post-marketing surveillance
• REMS (Risk Evaluation and Mitigation Strategies): For high-risk drugs (thalidomide analogs)

Modern Thalidomide Use

Reintroduced under strict REMS for:

• Multiple myeloma (with dexamethasone)
• Erythema nodosum leprosum (ENL)
• Mandatory pregnancy prevention program (contraception, pregnancy testing, registry)

Thalidomide's legacy: No drug reaches patients without rigorous teratogenicity assessment. The "thalidomide babies" and their families continue to advocate for recognition and support globally.